title: Surveillance for adverse drug reactions to combination antimalarial therapy with sulfadoxine-pyrimethamine plus artesunate in Peru.
abstract: In 2001, Peru changed its treatment policy for uncomplicated Plasmodium falciparum malaria on the northern Pacific Coast to sulfadoxine-pyrimethamine with atresunate (SP-AS). Because Peru was the first country in the Americas to adopt this combination therapy, we established a surveillance system in the region to assess the frequency of new or worsening symptoms after starting therapy. Over a period of two years, 1,552, or approximately two-thirds of all patients with uncomplicated P. falciparum malaria who had received SP-AS on the northern coast were followed up. Of these, 8.8% reported at least one adverse effect, with the most common being vomiting, nausea, headache, abdominal pain, dizziness, and fever; no severe adverse effects related to SP-AS therapy were identified. Treatment of uncomplicated malaria with SP-AS was associated with a low frequency of mild adverse effects in Peru, and therefore should be considered as a first-line therapy in areas of the Americas where SP efficacy is still high.
authors.affiliation: U.S. Naval Medical Research Center Detachment Lima, Peru. javier.cairolavado@yale.edu
authors.forename: Javier
authors.initials: J
authors.lastname: Cairo
authors.forename: Salomón
authors.initials: S
authors.lastname: Durand
authors.forename: Wilmer
authors.initials: W
authors.lastname: Marquiño
authors.forename: César
authors.initials: C
authors.lastname: Cabezas
authors.forename: Arnaldo
authors.initials: A
authors.lastname: Lachira
authors.forename: Fernando
authors.initials: F
authors.lastname: Quintana
authors.forename: Walter
authors.initials: W
authors.lastname: Vegas
authors.forename: Trenton K
authors.initials: TK
authors.lastname: Ruebush
authors.forename: Gregory
authors.initials: G
authors.lastname: Utz
authors.forename: David J
authors.initials: DJ
authors.lastname: Bacon
mesh_terms: D000962:Antimalarials / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D037621:Artemisinins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000077332:Artesunate; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000453:epidemiology*; D010568:Peru / Q000453:epidemiology; D011739:Pyrimethamine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013413:Sulfadoxine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000962:Antimalarials; D037621:Artemisinins; D004338:Drug Combinations; C001205:fanasil, pyrimethamine drug combination; D000077332:Artesunate; D013413:Sulfadoxine; D011739:Pyrimethamine